Long-term efficacy of lebrikizumab observed in the treatment of moderate and severe eczema

In patients with moderate to severe atopic dermatitis (AD), lebrikizumab shows long-term efficacy, according to a study presented at the annual meeting of the European Academy of Dermatology and Venereology which was held from September 25 to 28 in Amsterdam.

Diamant Thaçi, Ph.D., of the University of Lübeck in Germany, and colleagues reported the effectiveness and long term safety from the ADjoin long-term extension study. Adults aged 18 years and older and teenagers aged 12 to <18 years were randomized to receive lebrikizumab 250 mg every other week (LEBQ2W) or placebo in the ADvocate 1 and 2 trials.

Read moreWhat changes have been made to the RSPO standards and are they consistent with EUDR standards?

Patients receiving lebrikizumab who met protocol-defined response criteria at 16 weeks were randomized to receive LEBQ2W, lebrikizumab 250 mg every four weeks (LEBQ4W), or placebo. Participants who completed 52 weeks were eligible to enroll in ADjoin and received the same treatment regimen. Efficacy was assessed through week 100 of ADjoin.

In total, 82 patients receiving LEBQ2W and 99 receiving LEBQ4W participated in ADjoin. Researchers found that among patients with Investigator Global Assessment (IGA) scores of 0/1 at week 16 in the LEBQ2W and LEBQ4W groups, respectively, 81.5 and 83.3 % maintained an IGA of 0/1 at week 52 (week 0 of ADjoin) and 82.9 and 84.0 % maintained an IGA of 0/1 at week 152.

Read moreAltered mineral water: two investigations opened in Paris targeting Nestlé and Sources Alma

Among patients with a 75 % improvement in the Eczema Area and Severity Index (EASI 75) at week 16 in the LEBQ2W and LEBQ4W groups, 96.3 and 93.7 % and 90.5 and 94.1 % maintained an EASI 75 at week 52 and week 152, respectively. Throughout the ADjoin study, 14.6 and 24.2 % of patients receiving LEBQ2W and LEBQ4W, respectively, used rescue medication.

"These three-year results provide compelling evidence of durable efficacy and a consistent safety profile," lead author Dr. Eric Simpson of Oregon Health & Science University in Portland said in a statement.

The study was funded by Eli Lilly, the manufacturer of lebrikizumab.

© 2024 HealthDay. All rights reserved.